E Fund Management Co. Ltd. Has $549,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

E Fund Management Co. Ltd. boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 34.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,860 shares of the company’s stock after purchasing an additional 12,569 shares during the period. E Fund Management Co. Ltd.’s holdings in Roivant Sciences were worth $549,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Roivant Sciences by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,023,027 shares of the company’s stock valued at $22,719,000 after buying an additional 99,148 shares during the period. Natixis Advisors L.P. acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at about $699,000. Swiss National Bank increased its stake in shares of Roivant Sciences by 8.1% in the fourth quarter. Swiss National Bank now owns 546,746 shares of the company’s stock valued at $6,140,000 after buying an additional 41,000 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at about $36,000. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of Roivant Sciences by 27.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 275,303 shares of the company’s stock valued at $3,092,000 after buying an additional 59,553 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Down 1.5 %

NASDAQ:ROIV traded down $0.17 on Wednesday, hitting $11.21. The stock had a trading volume of 5,092,369 shares, compared to its average volume of 6,515,017. The business’s fifty day moving average is $10.87 and its 200 day moving average is $10.44. The company has a market cap of $9.03 billion, a PE ratio of 2.16 and a beta of 1.30. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The company had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. On average, equities research analysts expect that Roivant Sciences Ltd. will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. TheStreet raised Roivant Sciences from a “d” rating to a “c+” rating in a research note on Tuesday, February 13th. Wolfe Research began coverage on Roivant Sciences in a research note on Thursday, February 15th. They set an “outperform” rating and a $17.00 target price for the company. Deutsche Bank Aktiengesellschaft raised their target price on Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. The Goldman Sachs Group raised their target price on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 22nd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.90.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 96,950 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.60% of the stock is currently owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.